Targeted therapy in renal cell carcinoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-04

AUTHORS

Jean-Jacques Patard, Damien Pouessel, Karim Bensalah, Stéphane Culine

ABSTRACT

OBJECTIVE: To present an update on anti-angiogenic drugs in the treatment of metastatic renal cell carcinoma. RECENT FINDINGS: A better understanding of molecular pathways that are involved in clear cell carcinomas has led to the development of multiple targeted therapies with significant clinical benefits. Two tyrosine kinase inhibitors targeting the vascular endothelial growth factor (VEGF) receptor have been shown to improve the progression-free survival of patients in first-line (Sunitinib vs. interferon-alpha) or second-line treatment (Sorafenib vs. placebo). Temsirolimus, an agent that inhibits the serine-threonine kinase activity of the mammalian target of rapamycin, offers better overall survival than interferon in patients with poor-risk characteristics. Finally, Bevacizumab, which is an antibody directed against VEGF, in association with IFN is providing substantial response rates and increased progression-free survival compared to IFN alone. CONCLUSION: Four major drugs or regimens with proven efficacy are now available in first and second line therapy in metastatic renal cell carcinoma (mRCC). Further studies are needed to determine the optimal combinations of these agents in metastatic disease and to assess their impact in the adjuvant setting. More... »

PAGES

135-140

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00345-008-0237-4

DOI

http://dx.doi.org/10.1007/s00345-008-0237-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1039396334

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18265991


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neovascularization, Pathologic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Signal Transduction", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "l'H\u00f4pital Pontchaillou", 
          "id": "https://www.grid.ac/institutes/grid.414271.5", 
          "name": [
            "Department of Urology, Rennes University Hospital, CHU Pontchaillou, rue Henri le Guillou, 35033, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Patard", 
        "givenName": "Jean-Jacques", 
        "id": "sg:person.01117100145.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117100145.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "UniCancer Group", 
          "id": "https://www.grid.ac/institutes/grid.418189.d", 
          "name": [
            "Department of Medical Oncology, CRLC Val d\u2019Aurelle, Montpellier, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pouessel", 
        "givenName": "Damien", 
        "id": "sg:person.0656276246.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656276246.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "l'H\u00f4pital Pontchaillou", 
          "id": "https://www.grid.ac/institutes/grid.414271.5", 
          "name": [
            "Department of Urology, Rennes University Hospital, CHU Pontchaillou, rue Henri le Guillou, 35033, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bensalah", 
        "givenName": "Karim", 
        "id": "sg:person.01070707443.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070707443.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "UniCancer Group", 
          "id": "https://www.grid.ac/institutes/grid.418189.d", 
          "name": [
            "Department of Medical Oncology, CRLC Val d\u2019Aurelle, Montpellier, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Culine", 
        "givenName": "St\u00e9phane", 
        "id": "sg:person.01135615153.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135615153.17"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2007.11.1047", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000639352"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/14737140.5.6.1031", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002551076"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/mcb.22.20.7004-7014.2002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003444276"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.01.8234", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005188382"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.01.8234", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005188382"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.13.3751", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005904343"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.13.3215", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005937420"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.03.6723", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007324791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa065044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007947936"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.10.8613", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009417074"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa003013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009470130"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/canjclin.56.2.106", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013642811"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-04-1443", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014291431"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3816/cgc.2006.n.028", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017179806"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.ju.0000096060.92397.ed", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017578111"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.ju.0000096060.92397.ed", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017578111"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa021491", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020803009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.295.21.2516", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023194691"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(01)06103-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023853016"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa060655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025111240"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.juro.2007.01.136", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026516602"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11934-007-0017-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027097919", 
          "https://doi.org/10.1007/s11934-007-0017-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.11.5154", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027241718"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.eururo.2008.09.037", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031481266"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.02.2574", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035170611"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa066838", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037798278"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.08.185", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043632450"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(05)65640-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048312099"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/14651858.cd001425.pub2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053135144"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.11.123", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203185"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.02.122", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203409"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.8.2530", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549876"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.9.1928", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074630508"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-04", 
    "datePublishedReg": "2008-04-01", 
    "description": "OBJECTIVE: To present an update on anti-angiogenic drugs in the treatment of metastatic renal cell carcinoma.\nRECENT FINDINGS: A better understanding of molecular pathways that are involved in clear cell carcinomas has led to the development of multiple targeted therapies with significant clinical benefits. Two tyrosine kinase inhibitors targeting the vascular endothelial growth factor (VEGF) receptor have been shown to improve the progression-free survival of patients in first-line (Sunitinib vs. interferon-alpha) or second-line treatment (Sorafenib vs. placebo). Temsirolimus, an agent that inhibits the serine-threonine kinase activity of the mammalian target of rapamycin, offers better overall survival than interferon in patients with poor-risk characteristics. Finally, Bevacizumab, which is an antibody directed against VEGF, in association with IFN is providing substantial response rates and increased progression-free survival compared to IFN alone.\nCONCLUSION: Four major drugs or regimens with proven efficacy are now available in first and second line therapy in metastatic renal cell carcinoma (mRCC). Further studies are needed to determine the optimal combinations of these agents in metastatic disease and to assess their impact in the adjuvant setting.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00345-008-0237-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094127", 
        "issn": [
          "0724-4983", 
          "1433-8726"
        ], 
        "name": "World Journal of Urology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "26"
      }
    ], 
    "name": "Targeted therapy in renal cell carcinoma", 
    "pagination": "135-140", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "bbaa7f4e33046f1eb369e21c6989cce31eba8286dc5e37cd21c81d361a9f6fbc"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18265991"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8307716"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00345-008-0237-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1039396334"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00345-008-0237-4", 
      "https://app.dimensions.ai/details/publication/pub.1039396334"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000373_0000000373/records_13073_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00345-008-0237-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00345-008-0237-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00345-008-0237-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00345-008-0237-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00345-008-0237-4'


 

This table displays all metadata directly associated to this object as RDF triples.

211 TRIPLES      21 PREDICATES      66 URIs      27 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00345-008-0237-4 schema:about N03190848574440c2ae1d1d96db7f6598
2 N08a71a293f6d410098f8aaac4fc14cd8
3 N733619863f184bc7b5027941b4302b6c
4 Nc610c0e9fe844584bb2ac655605815c0
5 Ndcdb763e57614ae6988132c3b82fad38
6 Nfd4b83e42d2d404c9436c490ba43da24
7 anzsrc-for:11
8 anzsrc-for:1112
9 schema:author Nf6d95c1561024700a73cc4818f52f39e
10 schema:citation sg:pub.10.1007/s11934-007-0017-5
11 https://doi.org/10.1001/jama.295.21.2516
12 https://doi.org/10.1002/14651858.cd001425.pub2
13 https://doi.org/10.1016/j.eururo.2008.09.037
14 https://doi.org/10.1016/j.juro.2007.01.136
15 https://doi.org/10.1016/s0022-5347(05)65640-6
16 https://doi.org/10.1016/s0140-6736(01)06103-7
17 https://doi.org/10.1056/nejmoa003013
18 https://doi.org/10.1056/nejmoa021491
19 https://doi.org/10.1056/nejmoa060655
20 https://doi.org/10.1056/nejmoa065044
21 https://doi.org/10.1056/nejmoa066838
22 https://doi.org/10.1097/01.ju.0000096060.92397.ed
23 https://doi.org/10.1128/mcb.22.20.7004-7014.2002
24 https://doi.org/10.1158/0008-5472.can-04-1443
25 https://doi.org/10.1200/jco.1999.17.8.2530
26 https://doi.org/10.1200/jco.2000.18.9.1928
27 https://doi.org/10.1200/jco.2002.11.123
28 https://doi.org/10.1200/jco.2003.02.122
29 https://doi.org/10.1200/jco.2004.08.185
30 https://doi.org/10.1200/jco.2005.01.8234
31 https://doi.org/10.1200/jco.2005.02.2574
32 https://doi.org/10.1200/jco.2005.03.6723
33 https://doi.org/10.1200/jco.2007.10.8613
34 https://doi.org/10.1200/jco.2007.11.1047
35 https://doi.org/10.1200/jco.2007.11.5154
36 https://doi.org/10.1200/jco.2007.13.3215
37 https://doi.org/10.1200/jco.2007.13.3751
38 https://doi.org/10.1586/14737140.5.6.1031
39 https://doi.org/10.3322/canjclin.56.2.106
40 https://doi.org/10.3816/cgc.2006.n.028
41 schema:datePublished 2008-04
42 schema:datePublishedReg 2008-04-01
43 schema:description OBJECTIVE: To present an update on anti-angiogenic drugs in the treatment of metastatic renal cell carcinoma. RECENT FINDINGS: A better understanding of molecular pathways that are involved in clear cell carcinomas has led to the development of multiple targeted therapies with significant clinical benefits. Two tyrosine kinase inhibitors targeting the vascular endothelial growth factor (VEGF) receptor have been shown to improve the progression-free survival of patients in first-line (Sunitinib vs. interferon-alpha) or second-line treatment (Sorafenib vs. placebo). Temsirolimus, an agent that inhibits the serine-threonine kinase activity of the mammalian target of rapamycin, offers better overall survival than interferon in patients with poor-risk characteristics. Finally, Bevacizumab, which is an antibody directed against VEGF, in association with IFN is providing substantial response rates and increased progression-free survival compared to IFN alone. CONCLUSION: Four major drugs or regimens with proven efficacy are now available in first and second line therapy in metastatic renal cell carcinoma (mRCC). Further studies are needed to determine the optimal combinations of these agents in metastatic disease and to assess their impact in the adjuvant setting.
44 schema:genre research_article
45 schema:inLanguage en
46 schema:isAccessibleForFree false
47 schema:isPartOf Nd93caf829d734f62b1ac1d3d33a14514
48 Nf27d2d56a75d4c4190a1c31569fef0ac
49 sg:journal.1094127
50 schema:name Targeted therapy in renal cell carcinoma
51 schema:pagination 135-140
52 schema:productId N41ef9a708f424af1923138617bc04122
53 Na03eae57e7054266a84c2ba55412b239
54 Nbe3e9e56c7824708840cc1809a35cc5d
55 Ncabe2496b1c64673bb6a571255e01ab0
56 Nf74d6f4991e746368a3844dd91e0d4c4
57 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039396334
58 https://doi.org/10.1007/s00345-008-0237-4
59 schema:sdDatePublished 2019-04-11T14:27
60 schema:sdLicense https://scigraph.springernature.com/explorer/license/
61 schema:sdPublisher N00c23bfafdf14e15af24dc52f862c5bb
62 schema:url http://link.springer.com/10.1007%2Fs00345-008-0237-4
63 sgo:license sg:explorer/license/
64 sgo:sdDataset articles
65 rdf:type schema:ScholarlyArticle
66 N00c23bfafdf14e15af24dc52f862c5bb schema:name Springer Nature - SN SciGraph project
67 rdf:type schema:Organization
68 N03190848574440c2ae1d1d96db7f6598 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Kidney Neoplasms
70 rdf:type schema:DefinedTerm
71 N08a71a293f6d410098f8aaac4fc14cd8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Neovascularization, Pathologic
73 rdf:type schema:DefinedTerm
74 N0d3eeb1481274c22af10d7ea66b94fa1 rdf:first sg:person.01135615153.17
75 rdf:rest rdf:nil
76 N41ef9a708f424af1923138617bc04122 schema:name nlm_unique_id
77 schema:value 8307716
78 rdf:type schema:PropertyValue
79 N70ff20e2433b4ebd8b1da52dcc1e8072 rdf:first sg:person.01070707443.14
80 rdf:rest N0d3eeb1481274c22af10d7ea66b94fa1
81 N733619863f184bc7b5027941b4302b6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Angiogenesis Inhibitors
83 rdf:type schema:DefinedTerm
84 Na03eae57e7054266a84c2ba55412b239 schema:name doi
85 schema:value 10.1007/s00345-008-0237-4
86 rdf:type schema:PropertyValue
87 Nbe3e9e56c7824708840cc1809a35cc5d schema:name pubmed_id
88 schema:value 18265991
89 rdf:type schema:PropertyValue
90 Nc475f3cd21c847e08cdfe9edcc19747e rdf:first sg:person.0656276246.53
91 rdf:rest N70ff20e2433b4ebd8b1da52dcc1e8072
92 Nc610c0e9fe844584bb2ac655605815c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Humans
94 rdf:type schema:DefinedTerm
95 Ncabe2496b1c64673bb6a571255e01ab0 schema:name readcube_id
96 schema:value bbaa7f4e33046f1eb369e21c6989cce31eba8286dc5e37cd21c81d361a9f6fbc
97 rdf:type schema:PropertyValue
98 Nd93caf829d734f62b1ac1d3d33a14514 schema:issueNumber 2
99 rdf:type schema:PublicationIssue
100 Ndcdb763e57614ae6988132c3b82fad38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Signal Transduction
102 rdf:type schema:DefinedTerm
103 Nf27d2d56a75d4c4190a1c31569fef0ac schema:volumeNumber 26
104 rdf:type schema:PublicationVolume
105 Nf6d95c1561024700a73cc4818f52f39e rdf:first sg:person.01117100145.58
106 rdf:rest Nc475f3cd21c847e08cdfe9edcc19747e
107 Nf74d6f4991e746368a3844dd91e0d4c4 schema:name dimensions_id
108 schema:value pub.1039396334
109 rdf:type schema:PropertyValue
110 Nfd4b83e42d2d404c9436c490ba43da24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Carcinoma, Renal Cell
112 rdf:type schema:DefinedTerm
113 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
114 schema:name Medical and Health Sciences
115 rdf:type schema:DefinedTerm
116 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
117 schema:name Oncology and Carcinogenesis
118 rdf:type schema:DefinedTerm
119 sg:journal.1094127 schema:issn 0724-4983
120 1433-8726
121 schema:name World Journal of Urology
122 rdf:type schema:Periodical
123 sg:person.01070707443.14 schema:affiliation https://www.grid.ac/institutes/grid.414271.5
124 schema:familyName Bensalah
125 schema:givenName Karim
126 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070707443.14
127 rdf:type schema:Person
128 sg:person.01117100145.58 schema:affiliation https://www.grid.ac/institutes/grid.414271.5
129 schema:familyName Patard
130 schema:givenName Jean-Jacques
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117100145.58
132 rdf:type schema:Person
133 sg:person.01135615153.17 schema:affiliation https://www.grid.ac/institutes/grid.418189.d
134 schema:familyName Culine
135 schema:givenName Stéphane
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135615153.17
137 rdf:type schema:Person
138 sg:person.0656276246.53 schema:affiliation https://www.grid.ac/institutes/grid.418189.d
139 schema:familyName Pouessel
140 schema:givenName Damien
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656276246.53
142 rdf:type schema:Person
143 sg:pub.10.1007/s11934-007-0017-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027097919
144 https://doi.org/10.1007/s11934-007-0017-5
145 rdf:type schema:CreativeWork
146 https://doi.org/10.1001/jama.295.21.2516 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023194691
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1002/14651858.cd001425.pub2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053135144
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1016/j.eururo.2008.09.037 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031481266
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1016/j.juro.2007.01.136 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026516602
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1016/s0022-5347(05)65640-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048312099
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1016/s0140-6736(01)06103-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023853016
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1056/nejmoa003013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009470130
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1056/nejmoa021491 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020803009
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1056/nejmoa060655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025111240
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1056/nejmoa065044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007947936
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1056/nejmoa066838 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037798278
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1097/01.ju.0000096060.92397.ed schema:sameAs https://app.dimensions.ai/details/publication/pub.1017578111
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1128/mcb.22.20.7004-7014.2002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003444276
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1158/0008-5472.can-04-1443 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014291431
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1200/jco.1999.17.8.2530 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549876
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1200/jco.2000.18.9.1928 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074630508
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1200/jco.2002.11.123 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203185
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1200/jco.2003.02.122 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203409
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1200/jco.2004.08.185 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043632450
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1200/jco.2005.01.8234 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005188382
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1200/jco.2005.02.2574 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035170611
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1200/jco.2005.03.6723 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007324791
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1200/jco.2007.10.8613 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009417074
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1200/jco.2007.11.1047 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000639352
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1200/jco.2007.11.5154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027241718
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1200/jco.2007.13.3215 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005937420
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1200/jco.2007.13.3751 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005904343
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1586/14737140.5.6.1031 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002551076
201 rdf:type schema:CreativeWork
202 https://doi.org/10.3322/canjclin.56.2.106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013642811
203 rdf:type schema:CreativeWork
204 https://doi.org/10.3816/cgc.2006.n.028 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017179806
205 rdf:type schema:CreativeWork
206 https://www.grid.ac/institutes/grid.414271.5 schema:alternateName l'Hôpital Pontchaillou
207 schema:name Department of Urology, Rennes University Hospital, CHU Pontchaillou, rue Henri le Guillou, 35033, Rennes, France
208 rdf:type schema:Organization
209 https://www.grid.ac/institutes/grid.418189.d schema:alternateName UniCancer Group
210 schema:name Department of Medical Oncology, CRLC Val d’Aurelle, Montpellier, France
211 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...